keyword
MENU ▼
Read by QxMD icon Read
search

Type 2 diabetes and basal insulin

keyword
https://www.readbyqxmd.com/read/29143919/iglarlixi-reduces-glycated-hemoglobin-to-a-greater-extent-than-basal-insulin-regardless-of-levels-at-screening-post-hoc-analysis-of-lixilan-l
#1
Elisabeth Niemoeller, Elisabeth Souhami, Yujun Wu, Klaus H Jensen
INTRODUCTION: The treatment of patients with type 2 diabetes uncontrolled on basal insulin and oral glucose-lowering drugs was investigated previously in the LixiLan-L trial. In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phase, followed by treatment with a fixed-ratio combination of iGlar + lixisenatide (iGlarLixi) or iGlar alone over 30 weeks. In the study reported here, we investigated the achievement of glycemic control in those who completed the 30-week LixiLan-L trial, as assessed by change in glycated hemoglobin (HbA1c) levels from screening, both for the overall category and for screening HbA1c subcategories...
November 16, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29140602/the-cardiovascular-safety-of-long-acting-insulin-analogues-in-type-2-diabetes-is-there-a-better-basal-insulin
#2
Chia-Hsuin Chang, Lee-Ming Chuang
In 2008, the U.S. Food and Drug Administration requested that all new type 2 anti-diabetic drugs, including long-acting insulin analogues, need to be rigorously examined to preclude undesirable cardiovascular risks. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is the first trial to provide conclusive evidence of the cardiovascular safety of insulin glargine. A total of 12,537 people with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes were randomized to receive insulin glargine or standard care...
November 15, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/29129018/a-32-week-randomized-comparison-of-stepwise-insulin-intensification-of-biphasic-insulin-aspart-biasp%C3%A2-30-versus-basal-bolus-therapy-in-insulin-na%C3%A3-ve-patients-with-type-2-diabetes
#3
Sultan Linjawi, Byung-Wan Lee, Ömür Tabak, Susanna Lövdahl, Shanti Werther, Salahedeen Abusnana
INTRODUCTION: This 32-week, open-label, randomized, parallel-group, multinational trial aimed to compare the efficacy and safety of stepwise insulin intensification of biphasic insulin aspart 30 (BIAsp 30) relative to stepwise intensification of a basal-bolus regimen in insulin-naïve adults with type 2 diabetes (T2D) who continued pretrial treatment with metformin and sulfonylurea. METHODS: Adults with T2D were randomized into one of two treatment arms for 32 weeks: (1) BIAsp 30 once daily (OD), with the possibility of stepwise treatment intensification up to BIAsp 30 three times daily (TID); (2) insulin glargine OD, with the possibility of stepwise treatment intensification with insulin aspart up to TID...
November 11, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29119712/impact-of-delaying-treatment-intensification-with-a-glucagon-like-peptide-1-receptor-agonist-in-patients-with-type-2-diabetes-uncontrolled-on-basal-insulin-a-longitudinal-study-of-a-us-administrative-claims-database
#4
L Tong, C Pan, H Wang, M Bertolini, E Lew, L F Meneghini
AIM: To evaluate the effect of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) on clinical and economic outcomes in patients with type 2 diabetes (T2D). METHODS: We conducted a retrospective observational claims study using IMPACT(TM) , in adult patients with T2D who initiated basal insulin between 1 January 2005 and 31 December 2012 with or without OADs, but remained uncontrolled (glycated haemoglobin [HbA1c] ≥7.0%)...
November 8, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29116584/use-of-50-50-premixed-insulin-analogs-in-type-2-diabetes-systematic-review-and-clinical-recommendations
#5
REVIEW
Gary Deed, Gary Kilov, Trisha Dunning, Richard Cutfield, Jane Overland, Ted Wu
INTRODUCTION: Premixed insulin analogs represent an alternative to basal or basal-bolus insulin regimens for the treatment of type 2 diabetes (T2D). "Low-mix" formulations with a low rapid-acting to long-acting analog ratio (e.g., 25/75) are commonly used, but 50/50 formulations (Mix50) may be more appropriate for some patients. We conducted a systematic literature review to assess the efficacy and safety of Mix50, compared with low-mix, basal, or basal-bolus therapy, for insulin initiation and intensification...
December 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29115981/hyperuricemia-in-type-2-diabetic-model-kk-a-y-ta-mice-a-potent-animal-model-with-positive-correlation-between-insulin-resistance-and-plasma-high-uric-acid-levels
#6
Shin-Ichi Adachi, Fumiaki Yoshizawa, Kazumi Yagasaki
OBJECTIVE: Hyperuricemia is recognized as a main cause of gout. Accumulating clinical evidence suggests that hyperuricemia is strongly associated with insulin resistance and abnormal glucose metabolism. However, there seem no proper animal models for investigating such associations. Ideal animal model is considered to be hyperuricemic as well as diabetic. Selecting the KK-A(y)/Ta mouse model, the relationship between hyperuricemia and insulin resistance has been studied to characterize such an animal model...
November 7, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/29106046/retrospective-analysis-of-liraglutide-and-basal-insulin-combination-therapy-in-japanese-type-2-diabetes-the-association-between-remaining-%C3%AE-cell-function-and-the-achievement-of-the-hba1c-target-one-year-after-initiation
#7
Ryota Usui, Yui Sakuramachi, Yusuke Seino, Kenta Murotani, Hitoshi Kuwata, Hisato Tatsuoka, Yoshiyuki Hamamoto, Takeshi Kurose, Yutaka Seino, Daisuke Yabe
BACKGROUND AND AIMS: The glucose-lowering effects of the GLP-1 receptor agonist liraglutide have been shown to rely on remaining β-cell function. However, the possible associations of remaining β-cell function with the glucose-lowering effects of liraglutide in combination with basal insulin remain unknown and warrant investigation. METHODS: This is a single-center, retrospective, observational study conducted in a private hospital in Osaka, Japan. Type 2 diabetes patients who received a prescription change from insulin therapy, both multiple-dose insulin (MDI) and basal insulin-supported oral therapy (BOT), to liraglutide/basal insulin combination and continued the therapy for 54 weeks without additional oral anti-diabetic drugs (OAD) or bolus insulin were retrospectively analyzed...
November 6, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/29106039/a-european-multicentre-retrospective-non-interventional-study-eu-treat-of-the-effectiveness-of-insulin-degludec-after-switching-basal-insulin-in-a-population-with-type-1-or-type-2-diabetes
#8
Thorsten Siegmund, Nikolaos Tentolouris, Søren T Knudsen, Annunziata Lapolla, Rudolf Prager, Tra-Mi Phan, Michael Lyng Wolden, Bernd Schultes
AIMS: To evaluate the clinical effectiveness of switching to insulin degludec (IDeg) in insulin-treated patients with either T1DM or T2DM, in conditions of routine clinical care. MATERIALS AND METHODS: This was a multicentre, retrospective, chart review study. All patients had their basal insulin switched to IDeg at least 6 months before the start of data collection. Baseline was defined as the most recent recording during the 3-month period before first prescription of IDeg...
November 6, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29104217/codonopsis-lanceolata-water-extract-increases-hepatic-insulin-sensitivity-in-rats-with-experimentally-induced-type-2-diabetes
#9
Seong-Yeop Jeong, Suna Kang, Da Sol Kim, Sunmin Park
We examined the mechanisms and efficacy of Codonopsis lanceolata water extract (CLW) for treating type 2 diabetic (T2DM) symptoms. Partial pancreatectomized (Px) rats, a non-obese T2DM model, were provided high fat diets containing cellulose (control), 0.3% (CLW-L) or 1% CLW (CLW-H) for eight weeks. The positive control group was provided with rosiglitazone (20 mg/kg bw/day). The control group had lower epididymal fat masses than the CLW and the positive control groups, possibly due to urinary glucose loss, although CPT-1 and SIRT-1 expression was higher in the CLW group...
November 1, 2017: Nutrients
https://www.readbyqxmd.com/read/29100717/primary-care-physician-perspectives-on-basal-insulin-initiation-and-maintenance-in-patients-with-type-2-diabetes-mellitus
#10
Samaneh Kalirai, Judith Stephenson, Magaly Perez-Nieves, Michael Grabner, Irene Hadjiyianni, Caroline Geremakis, Roy Daniel Pollom, Beverly Reed, Lawrence Fisher
AIMS: To describe primary care physicians' (PCPs) perceptions of patient reactions and concerns about insulin initiation and identify opportunities for increased support. METHODS: Cross-sectional, online survey of PCPs prescribing basal insulin to adults with type 2 diabetes mellitus (T2DM). PCPs were identified from administrative claims of a large commercial health plan and descriptive results of PCP responses were reported. RESULTS: PCPs (N=100) treated an average of 17 patients receiving insulin during a typical week...
October 31, 2017: Primary Care Diabetes
https://www.readbyqxmd.com/read/29094298/optimizing-glycemic-control-through-titration-of-insulin-glargine-100-u-ml-a-review-of-current-and-future-approaches-with-a-focus-on-asian-populations
#11
REVIEW
Chaicharn Deerochanawong, Shailendra Bajpai, I Made Pande Dwipayana, Zanariah Hussein, Maria Aileen Mabunay, Reynaldo Rosales, Shih-Tzer Tsai, Man Wo Tsang
Various data have demonstrated inadequate glycemic control amongst Asians with type 2 diabetes mellitus (T2DM), possibly on account of suboptimal titration of basal insulin-an issue which needs to be further examined. Here we review the available global and Asia-specific data on titration of basal insulin, with a focus on the use of insulin glargine 100 U/mL (Gla-100). We also discuss clinical evidence on the efficacy and safety of titrating Gla-100, different approaches to titration, including some of the latest technological advancements, and guidance on the titration of basal insulin from international and local Asian guidelines...
December 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29090977/observational-registry-of-basal-insulin-treatment-in-patients-with-type-2-diabetes-in-china-safety-and-hypoglycemia-predictors
#12
Tingting Zhang, Linong Ji, Yan Gao, Puhong Zhang, Dongshan Zhu, Xian Li, Jiachao Ji, Fang Zhao, Heng Zhang, Xiaohui Guo
BACKGROUND: The Observational Registry of Basal Insulin Treatment (ORBIT) study evaluated the safety of basal insulin (BI) in real-world settings in China. METHODS: We analyzed 9002 patients with type 2 diabetes (T2D) inadequately controlled with oral hypoglycemic agents from 8 geographic regions and 2 hospital tiers in China who initiated and maintained BI treatment. Body weight and hypoglycemic episodes were recorded at baseline and 3 and 6 months. Serious adverse events (SAEs) were recorded at 3 and 6 months...
November 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/29083297/in-male-rats-the-ability-of-central-insulin-to-suppress-glucose-production-is-impaired-by-olanzapine-whereas-glucose-uptake-is-left-intact
#13
Chantel Kowalchuk, Celine Teo, Virginia Wilson, Araba Chintoh, Loretta Lam, Sri Mahavir Agarwal, Adria Giacca, Gary J Remington, Margaret K Hahn
BACKGROUND: Insulin receptors are widely expressed in the brain and may represent a crossroad between metabolic and cognitive disorders. Although antipsychotics, such as olanzapine, are the cornerstone treatment for schizophrenia, they are associated with high rates of type 2 diabetes and lack efficacy for illness-related cognitive deficits. Historically, this risk of diabetes was attributed to the weight gain propensity of antipsychotics, but recent work suggests antipsychotics can have weight-independent diabetogenic effects involving unknown brain-mediated mechanisms...
November 2017: Journal of Psychiatry & Neuroscience: JPN
https://www.readbyqxmd.com/read/29077488/perspectives-on-long-distance-air-travel-with-type-1-diabetes
#14
Jordan E Pinsker, Benjamen E Schoenberg, Colleen Garey, Asher Runion, Arianna Larez, David Kerr
We sought to determine the real-life experiences of individuals traveling long distance (across five or more time-zones) with type 1 diabetes (T1D). Five hundred three members of the T1D Exchange online community ( www.myglu.org ) completed a 45-question survey about their travel experiences flying long distance. The cohort was stratified by duration of T1D and whether or not participants used continuous subcutaneous insulin infusion (CSII) therapy and/or a continuous glucose monitor (CGM). In the last 5 years, 71% of participants had flown long distance...
October 27, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/29072163/effect-of-high-and-low-glycemic-index-breakfast-on-postprandial-metabolic-parameters-and-satiety-in-subjects-with-type-2-diabetes-mellitus-under-intensive-insulin-therapy-controlled-clinical-trial
#15
Daniela R Lobos, Isabella A Vicuña, Victoria Novik, Claudia A Vega
BACKGROUND AND AIM: The results of studies evaluating the metabolic effects of glycemic index (GI) in subjects with type 2 diabetes mellitus (DM2) have been contradictory. Consequently, the benefits of its application are controversial and polarized opinions of international organizations have been disclosed. The above situation leads this study to evaluate the acute effect of low and high GI breakfast on the glycemic response and satiety in subjects with DM2 under intensive insulin therapy (IIT)...
August 2017: Clinical Nutrition ESPEN
https://www.readbyqxmd.com/read/29068709/altered-patterns-of-early-metabolic-decompensation-in-type-1-diabetes-during-treatment-with-a-sglt2-inhibitor-an-insulin-pump-suspension-study
#16
Neha S Patel, Michelle A Van Name, Eda Cengiz, Lori R Carria, Stuart A Weinzimer, William V Tamborlane, Jennifer L Sherr
BACKGROUND: Enthusiasm for the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) as an adjunctive treatment in type 1 diabetes (T1D) has been offset by the possible increased risk of diabetic ketoacidosis (DKA). Since pump-treated T1D patients are susceptible to DKA due to infusion site problems, this study was undertaken to assess how treatment with SGLT2i affects patterns of early metabolic decompensation following suspension of basal insulin. METHODS: Ten T1D participants (age 19-35 years, duration 10 ± 8 years, A1c 7...
November 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/29065720/identifying-insulin-treatment-responders-with-a-composite-measure-beyond-hba1c-7-in-patients-with-type-2-diabetes
#17
Ignacio Conget, M Sue Kirkman, Dachuang Cao, Mayme Wong, Jesus Reviriego, David M Kendall
OBJECTIVES: Many insulin-treated patients with type 2 diabetes (T2D) do not reach hemoglobin A1c (HbA1c) <7% but have clinically relevant HbA1c reductions. Using an integrated database (IDB) of 53 insulin lispro clinical trials and a real-world evidence (RWE) database of T2D patients initiating insulin therapy, an expanded HbA1c measure was used to identify responders to insulin therapy. METHODS: Analysis included 4908 patients (IDB) and 1134 patients (RWE) with T2D treated with any insulin regimen with a baseline and ≥1 postbaseline HbA1c...
October 24, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29063511/cost-effectiveness-of-ideglira-versus-insulin-intensification-regimens-for-the-treatment-of-adults-with-type-2-diabetes-in-the-czech-republic
#18
Milan Kvapil, Martin Prázný, Pavel Holik, Karel Rychna, Barnaby Hunt
INTRODUCTION: The aim of this study was to evaluate the long-term cost-effectiveness of the insulin degludec/liraglutide combination (IDegLira) versus basal insulin intensification strategies for patients with type 2 diabetes mellitus (T2DM) not optimally controlled on basal insulin in the Czech Republic. METHODS: Cost-effectiveness was evaluated using the QuintilesIMS Health CORE Diabetes model, an interactive internet-based model that simulates clinical outcomes and costs for cohorts of patients with diabetes...
December 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29058131/insulin-and-its-cardiovascular-effects-what-is-the-current-evidence
#19
REVIEW
Sahana Pai Dongerkery, Pamela R Schroeder, Mansur E Shomali
PURPOSE OF REVIEW: In this article, we examine the nature of the complex relationship between insulin and cardiovascular disease. With metabolic abnormalities comes increased risk for cardiovascular complications. We discuss the key factors implicated in development and progression of cardiovascular disease, its relationship to insulin therapy, and what can be learned from large, recent cardiovascular outcome studies. RECENT FINDINGS: Preclinical studies suggest that insulin has positive effects of facilitating glucose entry into cells and maintaining euglycemia and negative effects of favoring obesity and atherogenesis under certain conditions...
October 23, 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/29056082/relationship-of-glucose-variability-with-glycated-hemoglobin-and-daily-mean-glucose-a-post-hoc-analysis-of-data-from-5-phase-3-studies
#20
Junxiang Luo, Yongming Qu, Qianyi Zhang, Annette M Chang, Scott J Jacober
BACKGROUND: The association of glucose variability (GV) with other glycemic measures is emerging as a topic of interest. The aim of this analysis is to study the correlation between GV and measures of glycemic control, such as glycated hemoglobin (HbA1c) and daily mean glucose (DMG). METHODS: Data from 5 phase 3 trials were pooled into 3 analysis groups: type 2 diabetes (T2D) treated with basal insulin only, T2D treated with basal-bolus therapy, and type 1 diabetes (T1D)...
October 1, 2017: Journal of Diabetes Science and Technology
keyword
keyword
32685
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"